Doxorubicinol  (Synonyms: Adriamycinol; DXR-OL)

Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.

Doxorubicinol inhibits diastolic function (i.e., increased resting pressure) of isolated papillary muscles^[1].
Doxorubicinol almost completely abrogates calcium pump activity at concentrations that significantly reduce diastolic function^[1].
Doxorubicinol inhibits Ca2+-stimulated ATPase activity of the sarcoplasmic reticulum of skeletal muscle and abolishes Na+/K+-ATPase activity of the sarcolemma in canine and rabbit heart preparations^[1].
Doxorubicinol inhibits the proliferation of PANC-1 cells with IC₅₀ value of 35.4 μM, PD PaCa cells with IC₅₀ value of 44.5 μM, WD PaCa cells with IC₅₀ value of 49.5^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

545.54

C₂₇H₃₁NO₁₁

54193-28-1

O=C1C2=C(C3=C(C(O)=C2C(C4=C1C=CC=C4OC)=O)[C@@H](O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)C[C@](O)([C@H](CO)O)C3)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Olson RD, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 1988 May;85(10):3585-9.  [Content Brief]